PL369371A1 - Nowe sposoby diagnostyki i leczenia guzów nowotworowych - Google Patents

Nowe sposoby diagnostyki i leczenia guzów nowotworowych

Info

Publication number
PL369371A1
PL369371A1 PL03369371A PL36937103A PL369371A1 PL 369371 A1 PL369371 A1 PL 369371A1 PL 03369371 A PL03369371 A PL 03369371A PL 36937103 A PL36937103 A PL 36937103A PL 369371 A1 PL369371 A1 PL 369371A1
Authority
PL
Poland
Prior art keywords
tumours
diagnosis
treatment
new methods
new
Prior art date
Application number
PL03369371A
Other languages
English (en)
Inventor
Christoph-Stephan Hilger
Dietmar Berndorff
Ludger Dinkelborg
Dieter Moosmayer
Giovanni Neri
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL369371A1 publication Critical patent/PL369371A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL03369371A 2002-01-03 2003-01-02 Nowe sposoby diagnostyki i leczenia guzów nowotworowych PL369371A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25

Publications (1)

Publication Number Publication Date
PL369371A1 true PL369371A1 (pl) 2005-04-18

Family

ID=26077560

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03369371A PL369371A1 (pl) 2002-01-03 2003-01-02 Nowe sposoby diagnostyki i leczenia guzów nowotworowych

Country Status (14)

Country Link
US (1) US20040001790A1 (pl)
EP (2) EP1461360B1 (pl)
JP (2) JP2005523887A (pl)
CN (1) CN1612895B (pl)
AU (1) AU2003210149B2 (pl)
BR (1) BR0306715A (pl)
CA (1) CA2468081A1 (pl)
CY (1) CY1110923T1 (pl)
IL (2) IL162201A0 (pl)
MX (1) MXPA04006517A (pl)
NO (1) NO20043246L (pl)
PL (1) PL369371A1 (pl)
RU (1) RU2352582C2 (pl)
WO (1) WO2003055917A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US20020197700A1 (en) * 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1619501B1 (en) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
JP2009535372A (ja) * 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
CA2682851C (en) * 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
EP2036576A1 (en) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
JP5985392B2 (ja) * 2009-07-22 2016-09-06 アクティニウム ファーマシューティカルズ インコーポレイテッド 放射性免疫複合体を生成するための方法
JP5892540B2 (ja) * 2009-12-25 2016-03-23 国立研究開発法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
CN104215668A (zh) * 2014-08-25 2014-12-17 浙江大学 基于theed纤维阵列的二氧化碳传感器及其制备方法
EP3378947B1 (en) * 2015-11-16 2024-01-24 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
IL310865A (en) * 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
EP4041213A4 (en) * 2019-10-29 2023-12-27 The Cleveland Clinic Foundation Psma-targeting imaging agents
ES2987329T3 (es) * 2020-05-22 2024-11-14 Philogen Spa Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
JPWO2025058000A1 (pl) 2023-09-13 2025-03-20

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065299C (en) * 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis

Also Published As

Publication number Publication date
CY1110923T1 (el) 2015-06-10
AU2003210149B2 (en) 2008-10-09
MXPA04006517A (es) 2005-03-31
JP2009209149A (ja) 2009-09-17
AU2003210149A1 (en) 2003-07-15
EP1461360A2 (en) 2004-09-29
US20040001790A1 (en) 2004-01-01
WO2003055917A3 (en) 2003-12-24
CN1612895B (zh) 2010-05-12
RU2352582C2 (ru) 2009-04-20
JP4663020B2 (ja) 2011-03-30
HK1076474A1 (zh) 2006-01-20
BR0306715A (pt) 2004-12-28
EP1461360B1 (en) 2010-08-18
CA2468081A1 (en) 2003-07-10
WO2003055917A2 (en) 2003-07-10
JP2005523887A (ja) 2005-08-11
CN1612895A (zh) 2005-05-04
NO20043246L (no) 2004-08-02
IL162201A0 (en) 2005-11-20
EP2239274A1 (en) 2010-10-13
RU2004123785A (ru) 2005-08-10
IL162201A (en) 2011-04-28

Similar Documents

Publication Publication Date Title
IL162201A0 (en) New methods for diagnosis and treatment of tumours
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
EP1551990A4 (en) DIAGNOSIS AND TREATMENT OF CHEMOSTORED TUMORS
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1641378A4 (en) METHOD AND DEVICES FOR TREATING SKIN Lions
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003900747A0 (en) Diagnosis and treatment of pancreatic cancer
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2003286741A8 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
PL1653982T3 (pl) Leczenie halitozy
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
GB0326578D0 (en) Cancer diagnosis and therapy
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)